SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	BCL2-like 1 (BCL-X_L; $BCL2_{L1}$)	SAR studies identified analogs of chelerythrine and sanguinarine that inhibit BCL-X_L and could be optimized to treat cancer. A fluorescence polarization assay identified three newly synthesized analogs of chelerythrine and five analogs of sanguinarine with more potent BCL-X_L binding and inhibitory activity than their respective parent compounds. The most potent analogs bound to different sites on the apoptosis-promoting protein, with the sanguinarine compounds binding to the BCL2 homology domain 1 and the chelerythrine compounds binding to the BCL2 homology domain groove. Additional studies are necessary to further enhance the potency and solubility of the compounds. *SciBX* 1(40); doi:10.1038/scibx.2008.967 Published online Nov. 6, 2008	Compounds unpatented; unavailable for licensing	Bernardo, P. *et al. J. Med. Chem.*; published online Oct. 17, 2008; doi:10.1021/jm8005433 **Contact:** Christina L.L. Chai, Agency for Science Technology and Research (A*STAR), Jurong Island, Singapore e-mail: christina_chai@ices.a-star.edu.sg